As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Krystal Biotech Inc. The largest reported stake is BlackRock, Inc.'s, at 11.6%. 5 filings are on record since March 27, 2026 (Schedule 13G/A, October 27, 2026).
Sell to companies like Krystal Biotech Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vanguard Portfolio Management · Sole voting: 25,577 · Shared voting: 0 · Sole dispositive: 1,312,431 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-30
- · Reporting person: BlackRock, Inc. · Sole voting: 3,358,055 · Shared voting: 0 · Sole dispositive: 3,427,645 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Holder: Krish S. Krishnan · Percent: 11.5% · SCHEDULE 13G/A
- · Holder: Vanguard Portfolio Management · Percent: 5.05% · SCHEDULE 13G
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Krystal Biotech Inc has 5 Schedule 13D or 13G filings on record since 2026-03-27. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 11.6% | 3,427,645 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| 11.5% | 3,388,283 | SCHEDULE 13G/A, 2026-05-04 | 2026-03-31 | |
| Vanguard Portfolio Management | 4.43% | 1,312,431 | SCHEDULE 13G/A, 2026-10-30 | 2026-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Krystal Biotech Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Krystal Biotech Inc and the records around it.
Krystal Biotech Inc elsewhere on the record
Companies that share a holder
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Krystal Biotech Inc
Get an email when Krystal Biotech Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Krystal Biotech Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Krystal Biotech Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Krystal Biotech Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,358,055 | 0 | 3,427,645 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| Vanguard Portfolio Management | 25,577 | 0 | 1,312,431 | 0 | SCHEDULE 13G/A, 2026-10-30 |
The latest filing identifies Krystal Biotech Inc by CUSIP 501147102 and gives its principal executive office as 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203 (SCHEDULE 13G/A, 2026-10-30).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 5.05% | SCHEDULE 13G |
| 2026-05-04 | Krish S. Krishnan | 11.5% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 11.6% | SCHEDULE 13G/A |
| 2026-10-30 | Vanguard Portfolio Management | 4.43% | SCHEDULE 13G/A |
Questions about who owns Krystal Biotech Inc
Who owns Krystal Biotech Inc?
On this page, 2 holders' latest ownership filings report 5% or more of Krystal Biotech Inc: BlackRock, Inc. (11.6%, Schedule 13G/A, filed 2026-10-27) and Krish S. Krishnan (11.5%, Schedule 13G/A, filed 2026-05-04).
Who are the largest shareholders of Krystal Biotech Inc?
By the share each holder's latest filing reports, the largest holders of Krystal Biotech Inc on this page are BlackRock, Inc. (11.6%) and Krish S. Krishnan (11.5%).
When did BlackRock, Inc. buy into Krystal Biotech Inc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-10-27, reporting 11.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Krystal Biotech Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.